Cytokinetics CYTK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$829.61M-34.8% | -$784.96M-33.2% | -$751.94M-30.5% | -$606.31M-11.2% | -$615.26M-16.0% | ||
| $11.2M+17.9% | $10.13M+6.2% | $9.65M-28.5% | $9.38M-27.4% | $9.5M-23.2% | ||
| $119.13M+19.4% | $112.29M+14.8% | $108.03M+18.6% | $102.69M+21.6% | $99.78M+27.1% | ||
| $4.82M+309% | $1.11M-92.8% | $1.56M— | $8.41M— | $1.18M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $41.76M+674% | $33.6M+137% | $17.31M-52.2% | $15.21M-56.4% | $5.39M-72.0% | ||
| $500K+113% | $2.93M+20.3% | $7.18M+149% | $8.98M+186% | -$3.82M-212% | ||
| -$11.83M— | -$6.25M— | —— | —— | —— | ||
| —— | —— | —— | $1.34M— | —— | ||
| -$523.85M-31.6% | -$510.01M-28.8% | -$432.93M-7.1% | -$426.92M-7.0% | -$398M+5.6% | ||
| $25.07M+162% | $24.81M+535% | $20.45M+659% | $11.8M+433% | $9.57M+844% | ||
| $1.01B-22.8% | $1.06B-17.8% | $838.65M-40.0% | $717.6M-44.9% | $1.31B+90.4% | ||
| —— | —— | —— | —— | $100.43M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $729.46M— | $547.1M— | $364.73M— | $182.37M— | ||
| $10.86M+1.9% | $10.81M+24.5% | $10.76M+79.1% | $10.71M+220% | $10.66M+1,411% | ||
| $47.33M— | $35.98M— | $27.81M— | $27.2M— | —— | ||
| —— | —— | —— | $683K-24.0% | $914K+4.1% | ||
| $3.3M— | $2.47M— | $2.43M— | —— | —— | ||
| $527.47M-36.6% | $524.46M-43.6% | $416.14M-62.1% | $89.1M-92.2% | $831.57M+150% | ||
| —— | —— | —— | -$786K-3,517% | -$88K-1,357% | ||
| —— | —— | —— | —— | —— | ||
| $14.85M-41.6% | $22.91M-11.8% | $20.51M-20.0% | $25.35M+126% | $25.41M+24.2% | ||
| $6.1M+578% | $4.2M+223% | $4.5M+4,400% | $4.5M+850% | $900K— | ||
| —— | $0+100% | -$11.25K+66.7% | -$22.5K0.0% | -$33.75K-200% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.34M— | —— | ||
| -$9.74M-26.8% | -$10.84M-49.6% | -$8.64M-36.0% | -$8.31M-79.9% | -$7.68M-156% | ||
| -$11.83M— | -$6.25M— | —— | —— | —— | ||
| $500K+113% | $2.93M+20.3% | $7.18M+149% | $8.98M+186% | -$3.82M-212% | ||
| -$11.68M+65.1% | -$15.98M+50.9% | -$20.6M+31.1% | -$29M-28.5% | -$33.47M-86.7% | ||
| —— | —— | -$18.1M-20.7% | -$30.5M-15,350% | -$15.7M— | ||
| $63.08M+19.5% | $58.37M+19.3% | $55.99M+24.0% | $54.39M+40.7% | $52.78M+58.0% | ||
| $6M+32.0% | $5.65M+30.9% | $5.2M+27.0% | $4.83M+23.0% | $4.55M+19.4% | ||
| $27.9M+112% | $22.9M+98.1% | $17.96M— | $15.8M— | $13.13M— | ||
| $86K— | $25K— | $36K— | $35K— | —— | ||
| $1.09B+28.6% | $1.1B+48.3% | $1.06B+61.2% | $953.05M+40.8% | $844.65M+6.2% | ||
| —— | —— | —— | $683K-24.0% | $914K+4.1% | ||
| —— | $175M-12.5% | $181.25M+11.5% | $187.5M+50.0% | $193.75M+121% | ||
| —— | —— | —— | —— | —— | ||
| $39.67M+27.4% | $35.98M-32.1% | $27.81M-47.2% | $27.2M-45.0% | $31.14M-29.9% | ||
| —— | —— | —— | $6.11M— | —— | ||
| —— | —— | —— | —— | $3.83M+2,053% | ||
| -$548.92M-34.7% | -$534.82M-33.8% | -$453.38M-11.4% | -$438.72M-9.3% | -$407.57M+3.5% | ||
| -$548.92M-34.7% | -$534.82M-33.8% | -$453.38M-11.4% | -$438.72M-9.3% | -$407.57M+3.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytokinetics generate?
- Cytokinetics (CYTK) generated -$523.8M in operating cash flow over the trailing twelve months.
- What is Cytokinetics's free cash flow?
- After $25.1M of capital expenditures, Cytokinetics's free cash flow was -$548.9M over the trailing twelve months, down 34.7% year over year.
- Where does Cytokinetics's cash flow data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
